422 related articles for article (PubMed ID: 31509236)
1. The IL-13-OVOL1-FLG axis in atopic dermatitis.
Furue K; Ito T; Tsuji G; Ulzii D; Vu YH; Kido-Nakahara M; Nakahara T; Furue M
Immunology; 2019 Dec; 158(4):281-286. PubMed ID: 31509236
[TBL] [Abstract][Full Text] [Related]
2. Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis.
Tsuji G; Hashimoto-Hachiya A; Kiyomatsu-Oda M; Takemura M; Ohno F; Ito T; Morino-Koga S; Mitoma C; Nakahara T; Uchi H; Furue M
Cell Death Dis; 2017 Jul; 8(7):e2931. PubMed ID: 28703805
[TBL] [Abstract][Full Text] [Related]
3. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
Moyle M; Cevikbas F; Harden JL; Guttman-Yassky E
Exp Dermatol; 2019 Jul; 28(7):756-768. PubMed ID: 30825336
[TBL] [Abstract][Full Text] [Related]
4. The role of the OVOL1-OVOL2 axis in normal and diseased human skin.
Tsuji G; Ito T; Chiba T; Mitoma C; Nakahara T; Uchi H; Furue M
J Dermatol Sci; 2018 Jun; 90(3):227-231. PubMed ID: 29454536
[TBL] [Abstract][Full Text] [Related]
5. Biologics for Atopic Dermatitis.
Boguniewicz M
Immunol Allergy Clin North Am; 2020 Nov; 40(4):593-607. PubMed ID: 33012322
[TBL] [Abstract][Full Text] [Related]
6. IL-13 antagonists in the treatment of atopic dermatitis.
Tubau C; Puig L
Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of Atopic Dermatitis: Current Paradigm.
Furue M; Ulzii D; Vu YH; Tsuji G; Kido-Nakahara M; Nakahara T
Iran J Immunol; 2019 Jun; 16(2):97-107. PubMed ID: 31182684
[TBL] [Abstract][Full Text] [Related]
8. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis.
Bakker DS; van der Wal MM; Heeb LEM; Giovannone B; Asamoah M; Delemarre EM; Drylewicz J; Nierkens S; Boyman O; de Bruin-Weller MS; Thijs JL; van Wijk F
J Invest Dermatol; 2021 Aug; 141(8):1943-1953.e13. PubMed ID: 33610558
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous atopic dermatitis in mice with a defective skin barrier is independent of ILC2 and mediated by IL-1β.
Schwartz C; Moran T; Saunders SP; Kaszlikowska A; Floudas A; Bom J; Nunez G; Iwakura Y; O'Neill L; Irvine AD; McKenzie ANJ; Ogg G; Walsh PT; Demengeot J; Fallon PG
Allergy; 2019 Oct; 74(10):1920-1933. PubMed ID: 30937919
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab for the treatment of adolescents with atopic dermatitis.
Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E; Bissonnette R; Ungar B; Suárez-Fariñas M; Ardeleanu M; Esaki H; Suprun M; Estrada Y; Xu H; Peng X; Silverberg JI; Menter A; Krueger JG; Zhang R; Chaudhry U; Swanson B; Graham NMH; Pirozzi G; Yancopoulos GD; D Hamilton JD
J Allergy Clin Immunol; 2019 Jan; 143(1):155-172. PubMed ID: 30194992
[TBL] [Abstract][Full Text] [Related]
12. Antioxidant Artemisia princeps Extract Enhances the Expression of Filaggrin and Loricrin via the AHR/OVOL1 Pathway.
Hirano A; Goto M; Mitsui T; Hashimoto-Hachiya A; Tsuji G; Furue M
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28892018
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
D'Erme AM; Romanelli M; Chiricozzi A
Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
[TBL] [Abstract][Full Text] [Related]
14. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis.
Salimi M; Barlow JL; Saunders SP; Xue L; Gutowska-Owsiak D; Wang X; Huang LC; Johnson D; Scanlon ST; McKenzie AN; Fallon PG; Ogg GS
J Exp Med; 2013 Dec; 210(13):2939-50. PubMed ID: 24323357
[TBL] [Abstract][Full Text] [Related]
15. The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis.
Silverberg JI; Kantor R
Dermatol Clin; 2017 Jul; 35(3):327-334. PubMed ID: 28577802
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity.
Saunders SP; Moran T; Floudas A; Wurlod F; Kaszlikowska A; Salimi M; Quinn EM; Oliphant CJ; Núñez G; McManus R; Hams E; Irvine AD; McKenzie AN; Ogg GS; Fallon PG
J Allergy Clin Immunol; 2016 Feb; 137(2):482-91. PubMed ID: 26299987
[TBL] [Abstract][Full Text] [Related]
17. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
Guttman-Yassky E; Kabashima K; Staumont-Salle D; Nahm WK; Pauser S; Da Rosa JC; Martel BC; Madsen DE; Røpke M; Arlert P; Steffensen L; Blauvelt A; Reich K
Allergy; 2024 Jun; 79(6):1560-1572. PubMed ID: 38563683
[TBL] [Abstract][Full Text] [Related]
18. Expression of barrier proteins in the skin lesions and inflammatory cytokines in peripheral blood mononuclear cells of atopic dogs.
Kanwal S; Singh SK; Soman SP; Choudhury S; Kumari P; Ram PK; Garg SK
Sci Rep; 2021 Jun; 11(1):11418. PubMed ID: 34075152
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of S100 fused-type proteins in an atopic dermatitis skin model.
Makino T; Mizawa M; Takemoto K; Yamamoto S; Shimizu T
Exp Dermatol; 2023 Dec; 32(12):2160-2165. PubMed ID: 36995036
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Dupilumab.
Harb H; Chatila TA
Clin Exp Allergy; 2020 Jan; 50(1):5-14. PubMed ID: 31505066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
